Effect of Bone Morphogenetic Protein 4 in the Human Brain Glioma Cell Line U251

Cell Biochemistry and Biophysics

Volumn 58, Issue 2, 2010, Pages 91-96

  Liu, Baohui ^a   Tian, Daofeng ^a   Yi, Wei ^a   Wu, Liquan ^a   Cai, Qiang ^a   Dong, Huimin ^a   Shen, Heng ^a   Ji, Baowei ^a   Wang, Long ^a   Zhang, Shenqi ^a   Ruan, Dong ^a   Chen, Qianxue ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Adriamycin; Bone morphogenetic protein 4; Mothers against decapentaplegic homolog 4; Target therapy; U251

Indexed keywords

BMP4 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN 4; SMAD4 PROTEIN; SMALL INTERFERING RNA;

ARTICLE; BRAIN TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; GLIOMA; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BONE MORPHOGENETIC PROTEIN 4; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOMA; HUMANS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD4 PROTEIN;

EID: 77956720949     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-010-9095-y     Document Type: Article

References (29)

1. Kim, E. S., Khuri, F. R., & Herbst, R. S. (2001). Epidermal growth factor receptor biology (IMC-C225). Current Opinion in Oncology, 13, 506-513.
2. Luwor, R. B., Kaye, A. H., & Zhu, H. J. (2008). Transforming growth factor-beta (TGF-beta) and brain tumours. Journal of Clinical Neuroscience, 15, 845-855.
3. Wong, M. L., Kaye, A. H., & Hovens, C. M. (2007). Targeting malignant glioma survival signalling to improve clinical outcomes. Journal of Clinical Neuroscience, 14, 301-308.
4. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031-1037.
5. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348, 994-1004.
6. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344, 783-792.
7. Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine, 353, 1659-1672.
8. Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Jr., Davidson, N. E., et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353, 1673-1684.
9. Joensuu, H., Kellokumpu-Lehtinen, P. L., Bono, P., Alanko, T., Kataja, V., Asola, R., et al. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. New England Journal of Medicine, 354, 809-820.
10. Jiang, H., Shang, X., Wu, H., Gautam, S. C., Al-Holou, S., Li, C., et al. (2009). Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. Journal of Experimental Therapeutics and Oncology, 8, 25-33.
11. Moore, L. M., Holmes, K. M., Smith, S. M., Wu, Y., Tchougounova, E., Uhrbom, L., et al. (2009). IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proceedings of the National Academy of Science USA, 106, 16675-16679.
12. Ducy, P., & Karsenty, G. (2000). The family of bone morphogenetic proteins. Kidney International, 57, 2207-2214.
13. Takae, R., Matsunaga, S., Origuchi, N., Yamamoto, T., Morimoto, N., Suzuki, S., et al. (1999). Immunolocalization of bone morphogenetic protein and its receptors in degeneration of intervertebral disc. Spine (Phila Pa 1976), 24, 1397-1401.
14. Sakou, T. (1998). Bone morphogenetic proteins: from basic studies to clinical approaches. Bone, 22, 591-603.
15. Wozney, J. M., Rosen, V., Celeste, A. J., Mitsock, L. M., Whitters, M. J., Kriz, R. W., et al. (1988). Novel regulators of bone formation: molecular clones and activities. Science, 242, 1528-1534.
16. Su, D., Zhu, S., Han, X., Feng, Y., Huang, H., Ren, G., et al. (2009). BMP4-Smad signaling pathway mediates adriamycin-induced premature senescence in lung cancer cells. Journal of Biological Chemistry, 284, 12153-12164.
17. Piccirillo, S. G., Reynolds, B. A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., et al. (2006). Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature, 444, 761-765.
18. Kang, Y. (2006). Pro-metastasis function of TGFbeta mediated by the Smad pathway. Journal of Cellular Biochemistry, 98, 1380-1390.
19. Massague, J., Blain, S. W., & Lo, R. S. (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. Cell, 103, 295-309.
20. Deng, H., Ravikumar, T. S., & Yang, W. L. (2009). Overexpression of bone morphogenetic protein 4 enhances the invasiveness of Smad4-deficient human colorectal cancer cells. Cancer Letters, 281, 220-231.
21. Miyaki, M., & Kuroki, T. (2003). Role of Smad4 (DPC4) inactivation in human cancer. Biochemical and Biophysical Research Communications, 306, 799-804.
22. Arteaga, C. L., & Baselga, J. (2004). Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell, 5, 525-531.
23. Newell, D. R. (2005). How to develop a successful cancer drug-molecules to medicines or targets to treatments? European Journal of Cancer, 41, 676-682.
24. Chen, Y. N., Mickley, L. A., Schwartz, A. M., Acton, E. M., Hwang, J. L., & Fojo, A. T. (1990). Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. Journal of Biological Chemistry, 265, 10073-10080.
25. Kim, J. H., Lee, G. E., Kim, J. C., Lee, J. H., & Chung, I. K. (2002). A novel telomere elongation in an adriamycin-resistant stomach cancer cell line with decreased telomerase activity. Molecules and Cells, 13, 228-236.
26. Gottlieb, J. A., Gutterman, J. U., McCredie, K. B., Rodriguez, V., & Frei, E., I. I. I. (1973). Chemotherapy of malignant lymphoma with adriamycin. Cancer Research, 33, 3024-3028.
27. Katagiri, H., Sato, K., Takahashi, M., Sugiura, H., Yamamura, S., & Iwata, H. (1997). Use of adriamycin-impregnated methylmethacrylate in the treatment of tumor metastases in the long bones. Archives of Orthopaedic and Trauma Surgery, 116, 329-333.
28. Miyazono, K. (2000). Positive and negative regulation of TGF-β signaling. Journal of Cell Science, 113, 1101-1109.
29. Goto, K., Kamiya, Y., Imamura, T., Miyazono, K., & Miyazawa, K. (2007). Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors. Journal of Biological Chemistry, 282, 20603-20611.